Drugs and therapies
Discover the latest developments in drugs and therapies, covering drug discovery, biologics, vaccines, immunotherapies, gene and cell therapies, drug delivery technologies and novel therapeutic modalities advancing treatment options across a wide range of diseases.
Webinars and whitepapers
- Previous
- Next
Drugs and therapies
ArticleOrgan chips move closer to drug discovery pipelines
From uncovering new drug targets to predicting human toxicity, organ chips are showing what they could bring to drug discovery. Professor Donald Ingber of Harvard University discusses where the technology is heading next.
ArticleAI’s real value in drug discovery may be choosing the right experiment
AI is becoming more capable, but its value still depends on the data, questions and decisions behind it. Where is it genuinely improving drug discovery and where do the limitations remain?
ArticleFrom R&D to QC: building a single analytical strategy for cell and gene therapies
From early research to quality control, maintaining analytical continuity is no easy task. Could a single sequencing workflow help simplify analytical assessment?
ArticleAntibody recycling, FcRn and the next generation of biologics
One receptor can protect antibodies from degradation, extend their half-life and become a drug target itself. Explore the science behind FcRn and how researchers measure its function.
Join now
Unlock exclusive industry insights
- Bookmark articles and resources to access anytime
- Enjoy free access to industry leading resources, webinars and insights
- Stay informed with the latest news and breakthroughs
- Receive updates and recommendations tailored to your research interests
InterviewThe global push to reduce animal testing in drug development
Non-animal methods are already used throughout early drug discovery, yet animal testing continues to dominate regulatory safety assessment. Recent initiatives suggest change is coming, but significant scientific and practical challenges remain.
ArticleDrug development has changed. Bioanalysis is changing with it
As drug developers pursue increasingly complex therapies, traditional bioanalytical approaches are being put to the test. How is the field adapting to meet these new demands?
ArticleSmall tags, big advances: studying endogenous proteins in their native context
By combining CRISPR knock-in with small peptide tags, researchers can study proteins in their native cellular context, generating more predictive data for translational drug discovery.
ReportContext is everything: how spatial biology is changing our understanding of disease
Studying individual cells has revolutionised biomedical research, but it doesn’t tell the whole story. Discover how spatial biology is revealing disease mechanisms with implications for biomarkers, immunotherapy and drug development.
ArticleFlow-based human tumour models reveal immune responses missed by static culture
Static cultures can miss critical immune–tumour interactions. Learn how the Mera™ flow-based human tissue model better captures T-cell activity to strengthen preclinical immunotherapy research.
ArticlePomegranate-derived compound shows therapeutic potential in heart disease
Researchers at Cardiff University have identified urolithin A – a compound produced by gut bacteria during the metabolism of substances found in pomegranates – as a new approach for treating cardiovascular disease.
ArticleAACR 2026 part two: integrating AI, spatial biology and next-gen therapeutics
In part two of our AACR 2026 coverage, industry leaders were focussed on how the field is no longer constrained by data generation or molecular design, but by the challenge of connecting systems, standardising workflows and ensuring biological insights.
ReportAI in Drug Discovery: Progress, Limits and What Comes Next
AI has attracted enormous investment across drug discovery, but major questions still remain around validation, reproducibility and real-world application. In our latest Beyond the Lab report, experts discuss where the technology is starting to influence discovery workflows – and where limitations continue to slow adoption.
ArticleWhy targeted therapies are exposing the limits of animal models – and what comes next
Traditional preclinical models are struggling to keep pace with a new generation of targeted therapies. As regulators embrace new approach methodologies (NAMs), vascularised tissue platforms are offering a more human-relevant approach to predicting drug efficacy and safety.
ArticleFrom chemist to AI agent builder: inside the rise of agentic AI in drug discovery
Dr Raminderpal Singh speaks with Dr Srijit Seal about why specialised AI agents are outperforming general-purpose models in drug discovery and what a new consortium paper shows about their use in practice.
ArticleMachine learning identifies biological signals linked to emotional hunger
Researchers at Phenomix Sciences are using machine learning and genetic risk scoring to investigate emotional hunger, an obesity phenotype linked to emotional and reward-driven eating behaviours. Dr Timothy O’Connor discusses how the approach could improve patient stratification, obesity research and treatment selection.
ArticleBeyond tangles: why soluble intracellular tau should guide drug discovery
Tau tangles are a hallmark of Alzheimer’s disease and related disorders, but evidence suggests the real damage may come from rare, soluble tau species inside neurons. Targeting these hidden drivers of circuit dysfunction could be key to restoring memory and cognition.
ArticleWhy AI models need patient data to deliver in drug discovery
Despite rapid advances in AI, many drug discovery models still struggle to translate computational predictions into clinical outcomes. Thomas Clozel explains how Owkin is training AI on large-scale patient-derived data while integrating experimental and clinical validation directly into model development.
ArticleTurning GWAS signals into drug targets with scalable CRISPR
Genome-wide association studies have linked thousands of genetic variants to disease, yet most remain disconnected from drug-relevant biology. Neville Sanjana, Professor at New York University and Core Faculty Member at the New York Genome Center, explains how scalable CRISPR screens systematically link noncoding variants to causal genes and therapeutic targets.
ArticleWhen antibiotics are not enough: the case for immune-engaging therapies
As antimicrobial resistance grows and patient populations become more complex, the limitations of antibiotics are becoming harder to ignore. Dr Helen Bright, CSO at Centauri Therapeutics, discusses a new approach that targets both the pathogen and the host.
ArticleAACR 2026 part one: AI design, precision biology and the next wave of oncology innovation
At AACR 2026, industry leaders discussed how oncology R&D is moving beyond isolated technological advances towards integrated discovery systems.